We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter
Est. Return
+4.99%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+788.65%
AUM
$110B
AUM Growth
+$11.3B
(+11%)
Cap. Flow
+$8.89B
Cap. Flow
% of AUM
8.09%
Top 10 Holdings %
Top 10 Hldgs %
35.27%
Holding
3,643
New
809
Increased
972
Reduced
1,047
Closed
744
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3.35B |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$2.85B |
| 3 |
Eli Lilly
LLY
|
+$999M |
| 4 |
Coca-Cola
KO
|
+$685M |
| 5 |
Broadcom
AVGO
|
+$616M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.38B |
| 2 |
Apple
AAPL
|
+$1.12B |
| 3 |
Netflix
NFLX
|
+$678M |
| 4 |
Boston Scientific
BSX
|
+$671M |
| 5 |
Cencora
COR
|
+$627M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.19% |
| 2 | Consumer Discretionary | 12.77% |
| 3 | Healthcare | 10.45% |
| 4 | Financials | 7.74% |
| 5 | Communication Services | 5.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
ARS Pharmaceuticals
SPRY
$606M
| $923K | ﹤0.01% |
79,214
-118,106
| -60% | -$1.15M |
|
|
BZUN
1952
Baozun
BZUN
$168M
| $922K | ﹤0.01% |
346,764
+76,928
| +29% | +$242K |
|
1953
Constellium
CSTM
$3.95B
| $919K | ﹤0.01% |
48,745
-67,265
| -58% | -$1.12M |
|
1954
COPT Defense Properties
CDP
$4.23B
| $919K | ﹤0.01% |
+33,050
| New | +$953K |
|
|
SUNS
1955
Sunrise Realty Trust
SUNS
$101M
| $916K | ﹤0.01% |
97,182
-15,664
| -14% | -$153K |
|
1956
Kanzhun
BZ
$6.89B
| $916K | ﹤0.01% |
+44,931
| New | +$971K |
|
1957
UGI
UGI
$7.56B
| $915K | ﹤0.01% |
+24,442
| New | +$866K |
|
1958
Oculis Holding
OCS
$712M
| $914K | ﹤0.01% |
+45,773
| New | +$916K |
|
1959
Replimune Group
REPL
$1.42B
| $910K | ﹤0.01% |
+93,585
| New | +$796K |
|
1960
Nature's Sunshine
NATR
$269M
| $909K | ﹤0.01% |
+42,145
| New | +$773K |
|
1961
Millicom
TIGO
$15.8B
| $908K | ﹤0.01% |
16,370
+5,460
| +50% | +$275K |
|
1962
DHI Group
DHX
$174M
| $907K | ﹤0.01% |
585,360
+484,019
| +478% | +$916K |
|
1963
CTS Corp
CTS
$1.79B
| $905K | ﹤0.01% |
21,113
-59,129
| -74% | -$2.48M |
|
1964
Lifecore Biomedical
LFCR
$179M
| $905K | ﹤0.01% |
110,621
-3,454
| -3% | -$25.6K |
|
1965
America's Car Mart
CRMT
$25.7M
| $905K | ﹤0.01% |
+35,819
| New | +$861K |
|
1966
MainStreet Bancshares
MNSB
$179M
| $902K | ﹤0.01% |
44,287
+31,833
| +256% | +$622K |
|
1967
iShares MSCI Emerging Markets ex China ETF
EMXC
$24.7B
| $897K | ﹤0.01% |
12,341
-167,059
| -93% | -$11.8M |
|
1968
Mission Produce
AVO
$1.15B
| $896K | ﹤0.01% |
+77,232
| New | +$925K |
|
1969
Green Plains
GPRE
$1.09B
| $894K | ﹤0.01% |
91,188
-260,360
| -74% | -$2.62M |
|
1970
AvePoint
AVPT
$2.91B
| $892K | ﹤0.01% |
64,199
-367,164
| -85% | -$5.07M |
|
1971
J&J Snack Foods
JJSF
$1.7B
| $892K | ﹤0.01% |
9,865
-41,003
| -81% | -$3.72M |
|
1972
Turkcell
TKC
$4.72B
| $884K | ﹤0.01% |
161,692
-1,326,559
| -89% | -$7.74M |
|
1973
SAB Biotherapeutics
SABS
$341M
| $884K | ﹤0.01% |
+236,460
| New | +$778K |
|
1974
Pharvaris
PHVS
$2.38B
| $883K | ﹤0.01% |
31,832
+4,736
| +17% | +$114K |
|
1975
Brown-Forman Class B
BF.B
$12.9B
| $878K | ﹤0.01% |
33,700
-3,435
| -9% | -$96.6K |
|
Similar funds
Marshall Wace's Q4 2025 Portfolio in Review
As of Q4 2025, Marshall Wace held 3,643 positions worth $110B, up 11% from $98.6B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Marshall Wace deployed $8.89B of net new capital in Q4 2025, opening 809 new positions and adding to 972 existing holdings. Its largest new stake was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Microsoft, an estimated $1.38B trimmed.
- Marshall Wace's largest Q4 2025 buy was Vanguard S&P 500 ETF: 4,580,704 shares worth $2.87B.
- Marshall Wace added most to iShares Core S&P 500 ETF in Q4 2025, an estimated $3.35B increase.
- Marshall Wace's biggest Q4 2025 reduction was Microsoft, cutting an estimated $1.38B.
- Marshall Wace fully exited Ares Management in Q4 2025, selling an estimated $146M.
- Marshall Wace's ten largest holdings make up 35% of its $110B portfolio in Q4 2025.
- Marshall Wace opened 809 new positions and closed 744 in Q4 2025.
- Marshall Wace's portfolio value rose 11% quarter-over-quarter to $110B.
Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.